Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

- PMLiVE

Janssen ‘extremely disappointed’ by NICE’s Olysio guidance

Hepatitis C drug only recommended use for one out of three licenced indications

Sanofi reception

Sanofi licenses cardiomyopathy programme in $200m deal

Has rights to three of MyoKardia’s programmes

- PMLiVE

Vifor Pharma appoints Dario Eklund

He takes on the role of head of international business operations

- PMLiVE

Gilead’s simtuzumab fails pancreatic cancer trial

Showed little difference in progression-free survival compared to placebo results

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

EU flag

Lantus faces first biosimilar rival in Europe

Sanofi prepares for insulin challenge from Boehringer and Lilly

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

Sanofi launches diabetes gaming app for children

Mission T1D aims to encourage discussion about how to live with the condition

- PMLiVE

AbbVie forges $1.5bn ageing disease alliance with Calico

Pharma company partners with Google’s health research business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links